Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02572206
Recruitment Status : Terminated (NIMH terminated study)
First Posted : October 8, 2015
Last Update Posted : September 28, 2016
Sponsor:
Collaborator:
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
New York State Psychiatric Institute

Brief Summary:
The primary goal of the present study is to evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related /mTOR kinase pathway dysregulation.

Condition or disease Intervention/treatment Phase
Schizophrenia Radiation: PET/SPECT Scan Device: MRI scan Phase 1

Detailed Description:
The investigators will focus on mGluR5 PET binding as a surrogate measure for level of activity of the mTOR kinase pathway. This study is being conducted by the New York State Psychiatric Institute (NYPSI) and the Research Foundation for Mental Hygiene Inc (RFMH) and will take place at Columbia University Medcial Center (CUMC) in New York City and at a research office in Strasburg, PA. Subjects (n=20) with the CNTNAP2 mutation with schizophrenia or a related condition will be recruited from the Amish and Mennonite communities and brought to CUMC for detailed investigation. Affected individuals will be compared to Old-Order Amish control patients drawn from the same families but not harboring CNTNAP2 mutations (n=20). The primary measure will consist of mGluR5 PET binding in DLPFC. In addition, secondary analyses will assess binding in other brain regions such as hippocampus and visual cortex. Exploratory measures, as well as relationships between PET mGluR5 binding and clinical symptomatology,will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers
Study Start Date : September 2015
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans

Arm Intervention/treatment
PET/SPECT and MRI scans

PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.

30 minute structural MRI will be obtained to permit co-registration of PET images.

Radiation: PET/SPECT Scan
PET scan will be performed on a mCT scanner.
Other Name: PET

Device: MRI scan
Structural MRI will be obtained to permit co-registration of PET images.
Other Name: MRI




Primary Outcome Measures :
  1. Level of MGluR5 PET binding in dorsolateral prefrontal cortex (DLPFC) in CNTNAP mutation carriers vs comparison subjects [ Time Frame: 90 minutes and the comparison will be binding in the specific regions listed (e.g., dorsolateral prefrontal cortex) controlled by binding in the cerebellum/input function. ]
    Evaluate the utility of mGluR5 binding as measured by PET as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.


Secondary Outcome Measures :
  1. Level of mGluR5 PET binding in hippocampus and primary visual cortex (occipial pole) [ Time Frame: 90 minutes and the comparison will be binding in the specific regions listed controlled by binding in the cerebellum/input function. ]
    Evaluate PET mGluR5 binding in other regions of potential relevance, including hippocampus and primary visual cortex in order to determine ideal regions of interest for future intervention studies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patients:

  • Meets DSM-5 diagnostic criteria for psychotic disorder, including schizophrenia, schizoaffective disorder or psychotic disorder not elsewhere classified
  • Aged 18-59 years
  • Genetic confirmation that patient carries CNTNAP2 mutation
  • All patients will be of Amish and/or Mennonite descent
  • Has a relative willing to be part of the study and this relative will travel with the participant to Columbia University Medical Center in New York City and back to Lancaster, PA
  • In the judgment of the participant's treating physician as well as the evaluating consenter, the patient is stable enough to travel and participate in the study

Control subjects:

  • Aged 18-59 years
  • Genetic confirmation that subject does not carry CNTNAP2 mutation
  • First-degree or second-degree relative of subject of Amish/Mennonite descent with CNTNAP2 mutation

Exclusion Criteria (for patients and controls):

  • Positive urine toxicology for drugs of abuse, including cannabinoids, amphetamine, benzodiazepines, barbiturates, cocaine, methadone, opiates, and phencyclidine
  • Positive history of severe neurological illness or history of brain trauma
  • Positive history of severe medical illness that would increase risk due to PET scan procedure, or interfere with interpretation of research findings
  • Low hemoglobin (Hb < 11 g/dL in males, Hb <10 g/dL in females)
  • Lifetime exposure to radiation in the workplace, or lifetime history of participation in nuclear medicine procedures, including research protocols. However, in case of previous exposure to radioactivity due to research studies, subjects will be eligible if all conditions listed below are fulfilled:

    • research studies in question have been performed in the context of a protocol from the Division of Translational Imaging (Anissa Abi-Dargham, M.D., Director) or as part of a research study within another division at Columbia University/NYSPI and the injected dose and dosimetry of the radiotracer are known
    • Except for research studies, the patient has had no lifetime exposure to radiation in the workplace or in nuclear medicine procedures
    • Adding the previous exposure to the exposure due to this study will result in a yearly cumulative exposure lower than the limit defined by the FDA for research subjects
  • Blood donation within 8 weeks of study
  • Presence of clinically significant brain abnormalities
  • For female patients of child-bearing age who are not surgically sterilized and between menarche and 1 year postmenopausal: Must test negative for pregnancy at the time of enrollment and prior to PET scan based on a serum pregnancy test. Women who are breast-feeding are also excluded.
  • Metal implants, pacemaker, other metal (e.g., shrapnel or surgical prostheses) or paramagnetic objects contained within the body which may present a risk to the subject or interfere with the MR scan, as determined in consultation with a neuroradiologist and according to the guidelines set forth in the following reference book commonly used by neuroradiologist: "Guide to MR procedures and metallic objects", F.G. Shellock, Lippincott Williams and Wilkins NY 2001.
  • Medicinal patch, unless removed prior to the MR scan.
  • Patients: Current treatment with clozapine and/or medications other than antipsychotics/PRN anxiolytics
  • Use of the medications that would interfere with mGluR5 binding, including lamotrigine, gabapentin, topiramate, phenobarbital, pregabalin, zonisamide, N-acetylcysteine, D-cycloserine
  • Control subjects: Lifetime history of antipsychotic or antidepressant use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02572206


Locations
Layout table for location information
United States, New York
New York State Psychiatric Insitute
New York, New York, United States, 10032
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey A Lieberman, MD New York State Psychiatric Institute
Layout table for additonal information
Responsible Party: New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT02572206    
Other Study ID Numbers: 7107
271201200007I-1-27100003-2 ( U.S. NIH Grant/Contract )
First Posted: October 8, 2015    Key Record Dates
Last Update Posted: September 28, 2016
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders